Cancer Stem Cell News Volume 10.10 | Mar 17 2021


    2021-03-17 | CSCN 10.10

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.10 – 17 March, 2021

    CDK8 Maintains Stemness and Tumorigenicity of Glioma Stem Cells by Regulating the C-MYC Pathway

    Investigators demonstrated how cyclin-dependent kinase 8 (CDK8) played an essential role in maintaining stemness and tumorigenicity in glioma stem cells.


    New human primary cancer-sourced blood products, immune cell subsets, and more. Click to view products.
    PUBLICATIONSRanked by the impact factor of the journal

    HER2-Targeted Antibody-Drug Conjugate Induces Host Immunity against Cancer Stem Cells

    The authors tested HER2-targeted antibody-drug conjugates in two immunocompetent mouse tumor models.
    [Cell Chemical Biology]

    AbstractGraphical Abstract

    Shc3 Promotes Hepatocellular Carcinoma Stemness and Drug Resistance by Interacting with β-Catenin to Inhibit Its Ubiquitin Degradation Pathway

    Scientists observed high Shc3 expression in patients with chemoresistant and recurrent hepatocellular carcinomas. Shc3 overexpression induced a significant increase in MDR1/P-glycoprotein expression, whereas Shc3 knockdown impaired this expression.
    [Cell Death & Disease]

    Full Article

    p97/VCP Is Highly Expressed in the Stem-Like Cells of Breast Cancer and Controls Cancer Stemness Partly through the Unfolded Protein Response

    Researchers examined p97 expression in the stem-like cancer cells or CSCs, a cell population that purportedly underscores cancer initiation, therapeutic resistance, and recurrence.
    [Cell Death & Disease]

    Full Article

    MAGI1 Inhibits the AMOTL2/p38 Stress Pathway and Prevents Luminal Breast Tumorigenesis

    The authors showed that the loss of the junctional scaffold protein MAGI1 was associated with bad prognosis in luminal breast cancer, and promoted tumorigenesis.
    [Scientific Reports]

    Full Article

    All-Trans Retinoic Acid and Protein Kinase C α/β1 Inhibitor Combined Treatment Targets Cancer Stem Cells and Impairs Breast Tumor Progression

    Employing hormone-independent mammary cancer models, Gö6976 and all-trans-retinoic acid combined treatment induced a synergistic reduction in proliferative potential that correlated with an increased apoptosis and RARs modulation towards an anti-oncogenic profile.
    [Scientific Reports]

    Full Article

    Correlation between the Expression of Cancer Stem Cell Marker BMI1 and Glioma Prognosis

    The authors investigated B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) expression in brain tumors using microarray datasets in ONCOMINE, which indicated that BMI1 levels were not commonly increased in clinical brain tumors.
    [Biochemical and Biophysical Research Communications]


    1 E-Cadherin Knockdown Induces Cancer Stem Cell-Like Phenotype and Drug Resistance

    CSC phenotype cells were isolated and the expression of stem cell marker and epithelial-mesenchymal transition associated gene was confirmed by various assays.
    [Biochemistry and Cell Biology]


    The Effect of hsa-miR-451b Knockdown on Biological Functions of Gastric Cancer Stem-Like Cells

    Gastric cancer stem-like cells were transfected by hsa-miR-451b inhibitor then researchers used real-time RT-PCR to evaluate its effect on the expression of hsa-miR-451b and two of its direct target genes, stemness markers such as KLF4, SOX2, CD44, OCT3/4 and NANOG genes.
    [Biochemical Genetics]

    Enter a contest to win a personalized lab coat by subscribing to Organoid News!

    Roles Played by YY1 in Embryonic, Adult and Cancer Stem Cells

    Since CSCs mirror the phenotypic behavior of stem cells, scientists describe the roles played by YY1 in embryonic and adult stem cells.
    [Stem Cell Reviews and Reports]

    Full ArticleGraphical Abstract

    From Sorting to Sequencing in the Molecular Era: The Evolution of the Cancer Stem Cell Model in Medulloblastoma

    The author examines the last two decades of CSC studies in the field. Seminal discoveries, emerging controversies and outstanding questions will be covered with a particular focus on medulloblastoma, the most common malignant primary brain tumor in children.
    [FEBS Journal]


    AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (Tivozanib) in Combination with OPDIVO® (Nivolumab) in Pivotal Phase III TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma

    AVEO Oncology announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA® in combination with OPDIVO®, Bristol Myers Squibb’s anti-PD-1 therapy, in the pivotal Phase III TiNivo-2 trial in patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.
    [AVEO Oncology]

    Press Release

    Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase I/II Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

    Rubius Therapeutics, Inc. announced initial clinical, pharmacodynamic and tumor trafficking data from its ongoing Phase I/II clinical trial of RTX-240 in patients with advanced solid tumors.
    [Rubius Therapeutics, Inc.]

    Press Release

    Children’s Cancer Research Fund Announces $10.5 Million in New Grants to Accelerate Childhood Cancer Research

    Children’s Cancer Research Fund is proud to award $10.5 million in its latest round of funding. The new grants support 12 research organizations that are working to improve treatment and outcomes for children and adolescents with cancer.
    [Children’s Cancer Research Fund]

    Press Release

    Leukopak Processing: Tips for Streamlined Cell Isolation

    March 31, 2021

    > See All Events


    Director – Ginny L. Clements Breast Cancer Research Institute

    University of Arizona Cancer Center – Tucson, Arizona, United States

    Research Coordinator – Breast Oncology

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Scholar Position – Hormone Therapy Resistance in Prostate Cancer

    Duke University – Durham, North Carolina, United States

    Postdoctoral Fellow Position – Sarcoma Biology

    The University of British Columbia – Vancouver, British Columbia, Canada

    Assistant Professor – Neuro-Oncology

    UC San Francisco – San Francisco, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter